Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Vet Pharmacol Ther ; 44(5): 799-807, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33893651

RESUMO

Sheep and goats are sharing different helminth parasites including Haemonchus contortus. Control of these helminths is based mainly on the use of anthelmintics. However, in goats, the application of anthelmintics is often carried out mainly at dosages determined for sheep without knowing the real effects and metabolism features. One of the several anthelmintic classes used against these parasites is (pro) benzimidazoles which are still widely in use in small ruminants in many countries. The objective of this study was to determine (i) the correlation between plasma and tissue or gastrointestinal content dispositions of ricobendazole (RBZ) in goats and (ii) the in vivo exposure of ricobendazole by H. contortus. Ten goats were experimentally infected with 10,000 larvae of H. contortus. Four weeks of post-infection, the animals received RBZ subcutaneously at 5 mg/kg body weight. Two goats were sacrificed per time at 1, 2, 4, 6 and 12 h after drug administration and, blood, bile, urine, liver, lung, muscle and kidney gastrointestinal tissues/fluids were collected. Adult H. contortus were collected from abomasum, and all samples were analysed by HPLC system. Ricobendazole (RBZ) and its sulphone metabolite were extensively excreted by urine and distributed to all tissues and digestive tract, mainly into the abomasum fluid. RBZ concentration in the lung and ABZSO2 in the kidney were relatively higher than those of other tissues, respectively. The parent drug and its metabolite were recovered in both male and female H. contortus. This study indicates that in goats the plasma concentration profiles of RBZ are strongly correlated with those achieved in different target tissues or fluids, which in turn, reflect the amount of drug taken up by parasites.


Assuntos
Anti-Helmínticos , Doenças das Cabras , Haemonchus , Preparações Farmacêuticas , Doenças dos Ovinos , Albendazol/análogos & derivados , Albendazol/uso terapêutico , Animais , Anti-Helmínticos/uso terapêutico , Feminino , Conteúdo Gastrointestinal , Doenças das Cabras/tratamento farmacológico , Cabras , Masculino , Ovinos , Doenças dos Ovinos/tratamento farmacológico
2.
Parasitology ; 147(13): 1425-1432, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32729453

RESUMO

In this study, we evaluated the efficacy, expressed as a mean weight decrease of the whole echinococcal cyst mass, of novel benzimidazole salt formulations in a murine Echinococcus granulosus infection model. BALB/c mice were intraperitoneally infected with protoscoleces of E. granulosus (genotype G1). At 9 months post-infection, treatment with albendazole (ABZ), ricobendazole (RBZ) salt formulations, and RBZ enantiomer salts (R)-(+)-RBZ-Na and (S)-(-)-RBZ-Na formulations were initiated. Drugs were orally applied by gavage at 10 mg kg-1 body weight per day during 30 days. Experimental treatments with benzimidazole sodium salts resulted in a significant reduction of the weight of cysts compared to conventional ABZ treatment, except for the (S)-(-)-RBZ-Na enantiomer formulation. Scanning electron microscopy and histological inspection revealed that treatments impacted not only the structural integrity of the parasite tissue in the germinal layer, but also induced alterations in the laminated layer. Overall, these results demonstrate the improved efficacy of benzimidazole salt formulations compared to conventional ABZ treatment in experimental murine cystic echinococcosis.


Assuntos
Albendazol/administração & dosagem , Anticestoides/administração & dosagem , Equinococose/tratamento farmacológico , Echinococcus granulosus/efeitos dos fármacos , Albendazol/análogos & derivados , Animais , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Sais/química
3.
ACS Appl Mater Interfaces ; 12(31): 35475-35481, 2020 Aug 05.
Artigo em Inglês | MEDLINE | ID: mdl-32658457

RESUMO

A cationic conjugated polyelectrolyte PPET3-N2 was used as a photosensitizer for photocatalytic oxidation of organic sulfides, including thioanisole, ethyl phenyl sulfide, 4-methylphenyl methyl sulfide, etc., to form sulfoxides with good yields and high selectivity. Oxidation reactions were performed in both batch and microfluidic reactors, where the microfluidic reactor can significantly promote the conversion of photocatalytic oxidation reaction to over 98% in about 8 min. Further studies of the photocatalytic oxidation of the antitumor drug ricobendazole in the microfluidic reactor demonstrate the potential application of the polymer material in organic reactions given its high selectivity, good efficiency, and operation convenience.

4.
Int J Pharm ; 585: 119501, 2020 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-32512225

RESUMO

Helminthic infections are produced by different types of worms and affect millions of people worldwide. Benzimidazole compounds such as ricobendazole (RBZ) are widely used to treat helminthiasis. However, their low aqueous solubility leads to poor gastrointestinal dissolution, absorption and potential lack of efficacy. The formulation of nanocrystals (NCs) have become the strategy of preference for hydrophobic drugs. In this work, we prepared RBZ NCs (RBZ-NCs) by an optimized combination of bead milling and spray-drying. Following the physicochemical characterization, a comparative pharmacokinetic evaluation of RBZ-NCs was performed in dogs using as controls a micronized powdered form of RBZ (mRBZ) and a physical mixture of drug and stabilizer 1:1 (PM). The particle size of the redispersed RBZ-NCs was 181.30 ± 5.93 nm, whereas DSC, PXRD and FTIR analyses demonstrated that the active ingredient RBZ remained physicochemically unchanged after the manufacture process. RBZ-NCs exhibited improved in vitro biopharmaceutical behaviour when compared to mRBZ. Consequently, the pharmacokinetic trial demonstrated a significant increase in the drug oral absorption, with an AUC0-∞ 1.9-fold higher in comparison to that obtained in animals treated with mRBZ. This novel formulation holds substantial potential for the development of new/alternative treatments for helminth infections both in human and veterinary medicine.


Assuntos
Albendazol/análogos & derivados , Nanopartículas/química , Tamanho da Partícula , Secagem por Atomização , Albendazol/síntese química , Albendazol/farmacocinética , Animais , Anti-Helmínticos/síntese química , Anti-Helmínticos/farmacocinética , Estudos Cross-Over , Cães , Feminino , Masculino
5.
J Pharm Biomed Anal ; 180: 113048, 2020 Feb 20.
Artigo em Inglês | MEDLINE | ID: mdl-31887670

RESUMO

Benzimidazoles are antiparasitic drugs having an extensive application field like agriculture, medicine, and especially in veterinary medicine. In this study, we report the effect of some benzimidazole drugs such as ricobendazole (RBZ), thiabendazole (TBZ), albendazole (ALBA) and oxfendazole (OFZ) on glutathione s-transferase (GST) enzyme activity. The kinetics studies, IC50 and Ki values of the tested drugs on GSTs enzyme activity were investigated. The obtained ranking of IC50 values were found to be approximately RBZ (53.31 µM, r2: 0.9778) < OFZ (57.75 µM, r2: 0.9630) < ALBA (63.00 µM, r2: 0.9443) < TBZ (69.30 µM, r2: 0.9491). And the obtained ranking of Ki values of the tested drugs (RBZ, TBZ, ALBA, and OFZ) for GSTs enzyme activity was found to be approximately 26.37 ±â€¯2.96, 44.01 ±â€¯5.74, 39.82 ±â€¯3.98 and 30.14 ±â€¯3.03 µM, respectively. Experimental results showed that tested the benzimidazoles drugs have some significant inhibitory effect on GSTs enzyme activity. And also, it was determined that RBZ, ALBA, OFZ are competitive inhibition, but TBZ is non-competitive inhibitors on GSTs enzyme activity. RBZ drug showed the best inhibitory effect with the lowest Ki value.


Assuntos
Antiparasitários/toxicidade , Benzimidazóis/toxicidade , Glutationa Transferase/antagonistas & inibidores , Cavalos , Fígado/efeitos dos fármacos , Drogas Veterinárias/toxicidade , Animais , Antiparasitários/química , Benzimidazóis/química , Relação Dose-Resposta a Droga , Técnicas In Vitro , Concentração Inibidora 50 , Fígado/enzimologia , Estrutura Molecular , Especificidade por Substrato , Drogas Veterinárias/química
6.
AAPS PharmSciTech ; 19(3): 1152-1159, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29218582

RESUMO

Albendazole (ABZ) and ricobendazole (RBZ) are referred to as class II compounds in the Biopharmaceutical Classification System. These drugs exhibit poor solubility, which profoundly affects their oral bioavailability. Micellar systems are excellent pharmaceutical tools to enhance solubilization and absorption of poorly soluble compounds. Polysorbate 80 (P80), poloxamer 407 (P407), sodium cholate (Na-C), and sodium deoxycholate (Na-DC) have been selected as surfactants to study the solubilization process of these drugs. Fluorescence emission was applied in order to obtain surfactant/fluorophore (S/F) ratio, critical micellar concentration, protection efficiency of micelles, and thermodynamic parameters. Systems were characterized by their size and zeta potential. A blue shift from 350 to 345 nm was observed when ABZ was included in P80, Na-DC, and Na-C micelles, while RBZ showed a slight change in the fluorescence band. P80 showed a significant solubilization capacity: S/F values were 688 for ABZ at pH 4 and 656 for RBZ at pH 6. Additionally, P80 micellar systems presented the smallest size (10 nm) and their size was not affected by pH change. S/F ratio for bile salts was tenfold higher than for the other surfactants. Quenching plots were linear and their constant values (2.17/M for ABZ and 2.29/M for RBZ) decreased with the addition of the surfactants, indicating a protective effect of the micelles. Na-DC showed better protective efficacy for ABZ and RBZ than the other surfactants (constant values 0.54 and 1.57/M, respectively), showing the drug inclusion into the micelles. Entropic parameters were negative in agreement with micelle formation.


Assuntos
Albendazol/análogos & derivados , Albendazol/química , Ácido Desoxicólico/química , Fluorescência , Micelas , Poloxâmero/química , Polissorbatos/química , Colato de Sódio/química , Solubilidade , Espectrometria de Fluorescência , Tensoativos/química , Termodinâmica
7.
J Vet Pharmacol Ther ; 41(1): 83-91, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28695609

RESUMO

The goals of the current study were to evaluate the potential pharmacokinetic (PK) interactions and the clinical efficacy occurring after the subcutaneous (s.c.) administration of ricobendazole (RBZ) and levamisole (LEV) given both separately and co-administered to calves naturally infected with susceptible gastrointestinal nematodes. The clinical efficacy was shown in two seasons, winter and spring, with predominance of different nematode populations. Groups of 15 calves were treated with RBZ alone, LEV alone and RBZ + LEV combination, and an untreated group was kept as a Control. RBZ and LEV plasma concentrations were quantified by HPLC. The clinical efficacy was determined by the faecal egg count reduction test. RBZ and LEV have similar plasma persistence, being detected in plasma over 24 hr post-treatment. No PK interactions were observed after the combined treatment, with similar PK parameters (p > .05) obtained for the single-drug and the combination-based strategy. In winter, the observed clinical efficacies were 96%, 99% and 100% for groups treated with RBZ, LEV and RBZ + LEV, respectively; however, in spring, the efficacies were 95%, 93% and 96% for the same groups. Remarkably, the combination was the only treatment that achieved 100% clinical efficacy against both Haemonchus spp and Ostertagia spp in winter; but the increased presence of Ostertagia spp. in spring (28% in untreated group) determined a tendency to reduced efficacies compared to winter time (only 10% of Ostertagia spp. in untreated group), even for the combined treatment. Overall, in a scenario where the nematode population is susceptible, the RBZ + LEV treatment may be a valid combination in cattle to delay the development of resistance, especially in winter when this combination achieved 100% of efficacy. Thus, selection of anthelmintic resistance will never occur. In fact, this is one of the greatest challenges for the whole cattle production system: to be one step ahead of anthelmintic resistance.


Assuntos
Albendazol/análogos & derivados , Antinematódeos/uso terapêutico , Levamisol/uso terapêutico , Albendazol/administração & dosagem , Albendazol/sangue , Albendazol/uso terapêutico , Animais , Antinematódeos/administração & dosagem , Bovinos , Doenças dos Bovinos/tratamento farmacológico , Doenças dos Bovinos/parasitologia , Quimioterapia Combinada/veterinária , Hemoncose/tratamento farmacológico , Hemoncose/veterinária , Haemonchus/efeitos dos fármacos , Injeções Subcutâneas/veterinária , Levamisol/administração & dosagem , Levamisol/sangue , Masculino , Ostertagia/efeitos dos fármacos , Ostertagíase , Contagem de Ovos de Parasitas/veterinária , Estações do Ano
8.
J Pharm Biomed Anal ; 139: 1-7, 2017 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-28258982

RESUMO

Albendazole (ABZ) is a sulfanyl-benzimidazole anthelmintic drug used worldwide in the treatment and prevention of parasitic diseases in animals and humans. Following oral administration, ABZ is rapidly oxidized into the pharmacologically active chiral sulfoxide metabolite known as ricobendazole (RBZ). As its achiral precursor, RBZ shows very low intestinal absorption due to its poor solubility in water (0.06mgmL-1). To the best of our knowledge, there is no known example in human medicine of a water-soluble salt form of racemic or enantiomerically pure RBZ. In the present study, we describe in detail the preparation of the sodium (Na) salt of the enantiomers of RBZ through a two-step process: i) the multi-milligram resolution of RBZ by HPLC on the amylose-based Chiralpak IG chiral stationary phase under polar organic mode; ii) the salification of the isolated enantiomers of RBZ by reaction with sodium hydroxide solution. The spectroscopic and chiroptical properties of the RBZ-Na enantiomers were determined. Due to their unique solubility in 0.01M phosphate buffer at physiological pH (14.49mgmL-1) and the high sample throughput obtained on semipreparative separation of the non-salified form, it is potentially possible to develop new anthelmintic enantiopure formulations with improved pharmacokinetic properties and lower toxicity.


Assuntos
Albendazol/análogos & derivados , Química Farmacêutica/métodos , Sódio/química , Albendazol/química , Albendazol/metabolismo , Cromatografia Líquida de Alta Pressão/métodos , Sódio/metabolismo , Solubilidade , Estereoisomerismo
9.
Vet Parasitol ; 234: 40-48, 2017 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-28115181

RESUMO

Nematodicidal combinations have been proposed as a valid strategy to achieve effective nematode control in the presence of drug resistance. The goals of this study were: (1) to compare the clinical efficacy (therapeutic response) of ivermectin (IVM) and ricobendazole (RBZ) given subcutaneously either by separate or combined administration to calves naturally infected with gastrointestinal nematodes resistant to IVM, and (2) to evaluate the potential pharmacokinetic (PK) and/or pharmacodynamic (PD) interactions occurring after the co-administration of both anthelmintics. Sixty male calves naturally infected with gastrointestinal nematodes resistant to IVM were randomly allocated into four groups (n=15). Untreated control: animals not receiving anthelmintic treatment; IVM alone: animals treated with IVM by subcutaneous (SC) injection (0.2mg/kg); RBZ alone: animals received RBZ by the SC route (3.75mg/kg); IVM+RBZ: animals treated with IVM and RBZ (0.2 and 3.75mg/kg, respectively), by SC injection in two separates sites. Eight animals of each treated group were randomly selected to perform the PK study. Plasma samples were taken from those animals up to 28days post-treatment. IVM and RBZ plasma concentrations were quantified by HPLC. The therapeutic response was determined by faecal egg count reduction test (FECRT). The proportions of third-stage larvae (L3) recovered from coprocultures were used to calculate the efficacy against the main parasite genera. The daily total egg deposition for each experimental group was estimated. Similar pharmacokinetic trends were obtained for both IVM and RBZ allying the single-drug and the combined treatments, which indicates the absence of PK interactions between both anthelmintics. The observed overall clinical drug efficacies were 48% (IVM alone), 94% (RBZ alone) and 98% (IVM+RBZ). Haemonchus spp. and Cooperia spp. were recovered in the coproculture after IVM treatment, suggesting that resistance to IVM includes both genera. In fact, the efficacy against Cooperia spp. was 83% (IVM), 98% (RBZ) and 98% (IVM+RBZ), while the efficacy against Haemonchus spp. was 0% (IVM), 97% (RBZ) and 100% (IVM+RBZ). The combination was the only treatment that achieved 100% clinical efficacy against IVM-resistant Haemonchus spp. The total egg excretion was reduced to 49.9% (IVM alone group), 6.3% (RBZ alone group) and 1.8% (IVM+RBZ combined group) compared to the untreated control. Although the combined treatment did not significantly increase the overall clinical efficacy in the current natural field conditions, an additive effect was achieved against IVM-resistant nematodes. In fact, the combination obtained significantly higher efficacy against IVM-resistant Haemonchus spp. than RBZ alone. Additionally, the epidemiological relevance of the reduction in the number of eggs excreted following the combined treatment is not negligible and should be taken into account in future studies. Further work is required to understand the advantages of nematodicidal combinations in different natural anthelmintic resistance scenarios.


Assuntos
Albendazol/análogos & derivados , Doenças dos Bovinos/parasitologia , Ivermectina/uso terapêutico , Infecções por Nematoides/veterinária , Albendazol/sangue , Albendazol/farmacocinética , Albendazol/farmacologia , Albendazol/uso terapêutico , Animais , Anti-Helmínticos/sangue , Anti-Helmínticos/farmacocinética , Anti-Helmínticos/farmacologia , Anti-Helmínticos/uso terapêutico , Bovinos , Doenças dos Bovinos/tratamento farmacológico , Interações Medicamentosas , Resistência a Medicamentos/efeitos dos fármacos , Quimioterapia Combinada , Ivermectina/sangue , Ivermectina/farmacocinética , Ivermectina/farmacologia , Masculino , Infecções por Nematoides/tratamento farmacológico , Infecções por Nematoides/parasitologia , Contagem de Ovos de Parasitas/veterinária , Distribuição Aleatória , Resultado do Tratamento
10.
Pesqui. vet. bras ; 32(5): 419-423, maio 2012. graf, tab
Artigo em Inglês | LILACS | ID: lil-626482

RESUMO

The aim was to evaluate for 75 days the impact on production of the remaining burden of ivermectin (IVM)-resistant parasites in naturally infected feedlot calves. The herds came from tick-infested areas of cattle breeding where the systematic use of IVM to control tick increases the gastrointestinal parasites resistant to this drug. This investigation was carried out in two commercial feedlots in Buenos Aires province. In feedlot A, two groups of 35 animal each received IVM 1% and the other received ricobendazole (RBZ) 10% respectively. The same was done in feedlot B. On day 0, two groups of 35 animals were made in feedlots A and B. Fecal samples were taken on days 0, 22, 54 and 75 pos-treatment (PT), and body weight was registered, from each animal. Fecal samples were processed for individual count of eggs per gram (EPG) and pooled fecal culture was carried out for identification of the parasite genus in each sampling. Fecal egg count reduction test (FECR) was calculated on day 22 PT. The study design used was a totally randomized block, with commercial feedlot and sex as block variables. For data analysis, a mixed model of the SAS statistical program was used. The FECR average on day 22 was 28.4% in the IVM group, and 94,2 % in the RBZ group . From this date on, significant differences in EPG were kept until day 54. EPG counts were only equal near the end of the trial, on day 75 (p=0.16). In both commercial feedlots, especially in the IVM group, Cooperia spp. was the most prevalent parasite in the fecal cultures. Significant differences in weight (P<0.01) on post-treatment day 75 was found between the average weight in the RBZ and the IVM group (246 vs. 238 kg respectively), what means a difference of 8.3% in gains. The importance for production in the antiparasite failure treatment in commercial feedlots was demonstrated, and the need of pos-treatment controls to evaluate the efficacy of the antiparasitic administered is emphasized.


O objetivo deste trabalho foi avaliar durante 75 dias o impacto sobre a produção da carga de parasita-ivermectina (IVM) resistentes remanescentes em bezerros naturalmente infectados no confinamento. Os rebanhos são provenientes de áreas infestadas por carrapatos, onde o uso sistemático de IVM para o controle do carrapato aumenta a resistência de parasita gastrintestinais a esta droga. Este trabalho foi realizado em dois confinamentos comerciais na província de Buenos Aires. Na fazenda A, dois grupos de 35 animais cada receberam IVM 1% e ricobendazole (RBZ) 10%, respectivamente. O mesmo foi feito no confinamento B. No dia 0, dois grupos de 35 animais foram feitos nas fazendas A e B. As amostras fecais foram tomadas nos dias 0, 22, 54 e 75 pós-tratamento (PT) e o peso corporal foi registrado, de cada animal. Amostras fecais foram processadas para a contagem individual de ovos por grama (EPG). Amostras fecais foram agrupadas para a identificação do gênero parasitária. O teste de redução de ovos fecais (TROF) foi calculado no dia 22 PT. O desenho do estudo utilizado foi aquele dos blocos inteiramente randomizados, sendo confinamento comercial e sexo as variáveis de bloco. Para a análise dos dados, um modelo misto do programa estatístico SAS foi utilizado. A média TROF no dia 22 foi de 28,4% no grupo IVM e 94,2% no grupo RBZ. A partir desta data, diferenças significativas na EPG foram mantidas até o dia 54. Contas de OPG só foram iguais perto do fim do estudo, no dia 75 (p=0,16). Em ambos os confinamentos comerciais, especialmente no grupo IVM, Cooperia spp. foram os parasitos mais prevalentes nas culturas fecais. Diferenças significativas no peso (P<0,01) 75 dias pós-tratamento foram encontradas entre o peso médio nos grupos RBZ e IVM (246 vs 238 kg, respectivamente), o que significa uma diferença de 8,3% nos ganhos. A importância para a produção no tratamento da insuficiência antiparasitários em confinamento comercial foi demonstrada, bem como a necessidade de controles pós-tratamento para avaliar a eficácia dos antiparasitários administrados é enfatizada.


Assuntos
Animais , Bovinos , Bovinos/crescimento & desenvolvimento , Doenças Parasitárias em Animais/terapia , Infestações por Carrapato/prevenção & controle , Ivermectina/administração & dosagem , Ivermectina/efeitos adversos , Antiparasitários/química , Doenças Parasitárias em Animais/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...